US Patent

US10251894 — Anticonvulsant activity of steroids

Method of Use · Assigned to University of California San Diego UCSD · Expires 2033-11-27 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of preventing, inhibiting, delaying, and/or mitigating seizures by administering a steroid, such as allopregnanolone.

USPTO Abstract

The present invention relates to methods of preventing, inhibiting, delaying, and/or mitigating seizures by administration of a steroid, e.g., a neurosteroid, e.g., allopregnanolone.

Drugs covered by this patent

Zulresso (BREXANOLONE) · Sage Therap

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2552`	—	Zulresso

Patent Metadata

Patent number: US10251894
Jurisdiction: US
Classification: Method of Use
Expires: 2033-11-27
Drug substance claim: No
Drug product claim: No
Assignee: University of California San Diego UCSD
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.